The pharmaceutical subsidiary of BAIYUNSHAN PH (600332.SH) has been granted a drug registration certificate by the National Medical Products Administration.

The certificate pertains to Cefaclor Sustained-Release Tablets (II), a second-generation cephalosporin antibiotic.

This medication is clinically indicated for treating infections caused by susceptible pathogenic bacteria, including acute bronchitis, acute exacerbations of chronic bronchitis, pharyngitis, tonsillitis, pneumonia, sinusitis, uncomplicated lower urinary tract infections, and skin and soft tissue infections.